CLAIMS:

1. A crystalline salt selected from:

(*R*)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethanolamine salt;

(*R*)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid diethylamine salt;

or pharmaceutically acceptable solvates and hydrates thereof,

wherein said diethanolamine salt has an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 8.5° ± 0.2°, 11.6° ± 0.2°, 11.8° ± 0.2°, and 12.1° ± 0.2°; and

wherein said diethylamine salt has an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 7.9° ± 0.2°, 8.5° ± 0.2°, 12.8° ± 0.2°, and 15.6° ± 0.2°.

2. A pharmaceutical composition comprising a crystalline salt according to claim 1, and a pharmaceutically acceptable carrier.

3. Use of a crystalline salt according to claim 1, in the manufacture of a medicament for the treatment of an S1P1 receptor-associated disorder.

4. A crystalline salt according to claim 1, for use in therapy.

5. The use according to claim 3, wherein said S1P1 receptor-associated disorder is selected from the group consisting of psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, and biliary cirrhosis.